资金持续布局，医疗创新ETF(516820)连续8天获资金净流入

Group 1 - The core viewpoint of the news highlights the mixed performance of the components of the CSI Pharmaceutical and Medical Device Innovation Index, with notable gains from Xingqi Eye Medicine and Xinhecheng, while Yingke Medical and Hualan Biological experienced declines [1] - The Medical Innovation ETF has seen continuous net inflows over the past eight days, with a peak single-day net inflow of 41.83 million yuan, totaling 156 million yuan, averaging 19.48 million yuan in daily net inflows [1] - The newly revised Implementation Regulations of the Drug Administration Law of the People's Republic of China will take effect on May 15, supporting the research and creation of new drugs based on clinical value and enhancing the quality and efficacy of generic drugs [1] Group 2 - The CSI Pharmaceutical and Medical Device Innovation Index selects 30 publicly listed companies with good profitability, growth potential, and research innovation capabilities to reflect the overall performance of the pharmaceutical and medical device sector [2] - As of December 31, 2025, the top ten weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index include WuXi AppTec, Hengrui Medicine, and Mindray Medical, accounting for a total of 63.75% of the index [2] Group 3 - The news does not contain any risk warnings or disclaimers, focusing solely on the performance and developments within the pharmaceutical and medical device industry.